Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
As Forte fails, who might yet improve the image of reverse mergers?
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Trillium gets a buyout while it's down
The latest deal over a CD47 asset has got investors wondering who could be next.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Sanofi Translates its mRNA interest into big bucks
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
After Immunogen and Sutro, Bristol buys into the folate story
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
